Yonsei University Reports Findings in Idiopathic Pulmonary Fibrosis (The preventative effects of statin on lung cancer development in patients with idiopathic pulmonary fibrosis using the National Health Insurance Service Database in Korea): Lung Diseases and Conditions – Idiopathic Pulmonary Fibrosis

2024 MAR 26 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily -- New research on Lung Diseases and Conditions - Idiopathic Pulmonary Fibrosis is the subject of a report. According to news reporting originating from Seoul, South Korea, by NewsRx correspondents, research stated, “Little is known about the effect of statin use in lung cancer development in idiopathic pulmonary fibrosis (IPF). We analyzed the database of the National Health Insurance Service to further investigate the clinical impacts of statin on lung cancer development and overall survival (OS) in IPF patients.”

Financial support for this research came from Bucheon St. Mary’s Hospital.

Our news editors obtained a quote from the research from Yonsei University, “The analysis included 9,182 individuals diagnosed with IPF, of which 3,372 (36.7%) were statin users. Compared to statin non-users, the time from diagnosis of IPF to lung cancer development and OS were longer in statin users in IPF patients. In Cox proportional hazard regression models, higher statin compliance, statin use, and being female had an inverse association with lung cancer risk, while older age at diagnosis of IPF and smoking history were associated with higher risk of lung cancer in IPF patients. For OS, statin use, female sex, higher physical activity frequency, and diabetes were associated with longer survival. In contrast, older age at diagnosis of IPF and smoking history were associated with shorter OS in IPF patients.”

According to the news editors, the research concluded: “These data from a large population indicate that statin had an independent protective association with lung cancer development and mortality in IPF patients.”

For more information on this research see: The preventative effects of statin on lung cancer development in patients with idiopathic pulmonary fibrosis using the National Health Insurance Service Database in Korea. PLOS ONE, 2024;19(3). PLOS ONE can be contacted at: Public Library Science, 1160 Battery Street, Ste 100, San Francisco, CA 94111, USA. (Public Library of Science - www.plos.org; PLOS ONE - www.plosone.org)

The news editors report that additional information may be obtained by contacting Nayoon Kang, Dept. of Statistics and Data Science, Yonsei University, Seoul, South Korea. Additional authors for this research include Yoo Jung Lee, Junghyun Nam, Eung Gu Lee, Jiwon Ryoo, Soon Seog Kwon, Yong Hyun Kim and Hye Seon Kang.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1371/journal.pone.0299484. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal PLOS ONE is: Public Library Science, 1160 Battery Street, Ste 100, San Francisco, CA 94111, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)